Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option

NCT03237780 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03237780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03237780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 20, 2018
Completion date
June 30, 2027
Enrollment
72 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced bladder urothelial carcinoma, locally advanced renal pelvis urothelial carcinoma, locally advanced ureter urothelial carcinoma, locally advanced urethral urothelial carcinoma, metastatic bladder urothelial carcinoma, metastatic renal pelvis urothelial carcinoma, metastatic ureter urothelial carcinoma, metastatic urethral urothelial carcinoma, recurrent bladder urothelial carcinoma, recurrent renal pelvis urothelial carcinoma, recurrent ureter urothelial carcinoma, recurrent urethral urothelial carcinoma, stage iii bladder cancer ajcc v8, stage iii renal pelvis cancer ajcc v8, stage iii ureter cancer ajcc v8, stage iii urethral cancer ajcc v8, stage iv bladder cancer ajcc v8, stage iv renal pelvis cancer ajcc v8, stage iv ureter cancer ajcc v8, stage iv urethral cancer ajcc v8, unresectable bladder urothelial carcinoma, unresectable renal pelvis urothelial carcinoma, unresectable ureter urothelial carcinoma, unresectable urethral urothelial carcinoma